Celcuity (CELC) Long-Term Debt Issuances (2024 - 2025)
Celcuity's (CELC) quarterly Long-Term Debt Issuances came in at -$7000.0 in Q4 2025, up 12.5% on a QoQ basis from -$8000.0 in Q3 2024.
Powered by 
Analysis
Celcuity (CELC) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Celcuity (CELC) has 2 years of Long-Term Debt Issuances data on file, last reported at -$7000.0 in Q4 2025.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$7000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15000.0 (down 87.5% YoY) and the FY2025 annual result came in at $27.7 million, down 53.15% from the prior year.
- Long-Term Debt Issuances grew to -$7000.0 in Q4 2025, from -$8000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of -$7000.0 in Q4 2025 to a low of -$8000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | - |